Literature DB >> 6446400

Cefoperazone: absorption, excretion, distribution, and metabolism.

K Shimizu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6446400

Source DB:  PubMed          Journal:  Clin Ther        ISSN： 0149-2918            Impact factor:   3.393


× No keyword cloud information.
  28 in total

1.  Multiple-dose pharmacokinetics and toleration of intravenously administered cefoperazone and sulbactam when given as single agents or in combination.

Authors:  D P Reitberg; T J Whall; M Chung; D Blickens; H Swarz; J Arnold
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

2.  Lung tissue concentrations of cefoperazone.

Authors:  K Wartenberg; J Tonak; W Knapp
Journal:  Infection       Date:  1983 Sep-Oct       Impact factor: 3.553

3.  Comparative pharmacokinetics of cefoperazone and cefamandole.

Authors:  S Srinivasan; E L Francke; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1981-02       Impact factor: 5.191

4.  Comparative pharmacokinetics of cefoperazone, cefotaxime, and moxalactam.

Authors:  B Kemmerich; H Lode; G Belmega; T Jendroschek; K Borner; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1983-03       Impact factor: 5.191

5.  Cefotaxime and desacetyl cefotaxime in human bile.

Authors:  F Kees; E Strehl; P Dominiak; H Grobecker; K Seeger; G Seidel; B Neuhaus; L Safrany
Journal:  Infection       Date:  1983 Mar-Apr       Impact factor: 3.553

6.  Anomalous effect of serum on the antimicrobial activity of cefoperazone.

Authors:  S D Lang; G L Cameron; P R Mullins
Journal:  Drugs       Date:  1981       Impact factor: 9.546

7.  Pharmacokinetics of cefoperazone (2.0 g) and sulbactam (1.0 g) coadministered to subjects with normal renal function, patients with decreased renal function, and patients with end-stage renal disease on hemodialysis.

Authors:  D P Reitberg; D A Marble; R W Schultz; T J Whall; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

8.  Antimicrobial activity and other in vitro properties of cefoperazone A, the principal metabolite of cefoperazone sodium.

Authors:  R N Jones; A L Barry
Journal:  Antimicrob Agents Chemother       Date:  1983-08       Impact factor: 5.191

9.  Cefoperazone pharmacokinetics in preterm infants.

Authors:  J A Bosso; G M Chan; J M Matsen
Journal:  Antimicrob Agents Chemother       Date:  1983-03       Impact factor: 5.191

10.  Cefoperazone pharmacokinetics in normal subjects and patients with cirrhosis.

Authors:  J A Boscia; O M Korzeniowski; R Snepar; W D Kobasa; M E Levison; D Kaye
Journal:  Antimicrob Agents Chemother       Date:  1983-03       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.